Finland · Delayed Price · Currency is EUR Canatu Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Transitioning from technology validation to scalable value creation, the company targets EUR 100–150 million revenue and 25–30% EBIT margin by 2030, driven by semiconductor growth and recurring revenues. High barriers to entry, disciplined capital allocation, and a flexible business model underpin expansion in automotive and medical diagnostics.
Fiscal Year 2025
-
Revenue declined 29% to EUR 15.6 million due to delayed reactor orders, but gross margin improved and automotive revenue more than doubled. Strong cash position enables continued investment, with key operational targets set for 2026 and new long-term guidance to be announced in March.
-
H1 revenue fell 34% year-over-year to $7.3 million due to semiconductor industry delays, but gross margin improved to 67.3%. Strategic investments in new facilities, medical diagnostics, and business development continue, with long-term targets maintained despite increased timeline risk.
Fiscal Year 2024
-
Revenue grew over 60% to EUR 22 million in 2024, led by semiconductor reactor shipments and strong inspection membrane sales. Gross margin was 62.5%, with adjusted EBIT margin at -21.9%. Long-term targets remain EUR 100 million revenue and 30%+ EBIT margin by 2027.
-
A full share deal with Lifeline SPAC I secures up to €105 million for growth, with a €230 million valuation and new institutional investors. The company targets over €100 million revenue and >30% EBIT by 2027, driven by proprietary CNT technology in semiconductors, automotive, and diagnostics.